Business
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and distribution of Valneva’s three proprietary vaccines in Germany. Under the agreed terms, CSL Seqirus will start commercializing Valneva’s single-dose chikungunya vaccine IXCHIQ® from July 2025, and Valneva’s Japanese Encephalitis vaccine IXIARO® a
About this update from Valneva Se
[{"type":"image","alt":"VALNEVA","displaySize":"","headline":null,"caption":"VALNEVA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9l2h5dKc1PlSY26lXUAWsA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/29df7eb71c048b91fe66a95a1cd8b1d6","width":300,"height":44}},"lazy":false},{"type":"text","content":"Saint-Herblain, France, June 26, 2025 – Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an exclusive agreement with CSL Seqirus, one of the world’s largest influenza vaccine companies, for the marketing and distribution of Valneva’s three proprietary vaccines in Germany.","length":317,"tagName":"p"},{"type":"text","content":"Under the agreed terms, CSL Seqirus will start commercializing Valneva’s single-dose chikungunya vaccine IXCHIQ® from July 2025, and Valneva’s Japanese Encephalitis vaccine IXIARO® and cholera/ETEC1 vaccine DUKORAL® from January 2026. This new agreement with CSL Seqirus replaces the marketing and distribution agreement Valneva signed with Bavarian Nordic in 20212, which is due to conclude at the end of December 2025.","length":420,"tagName":"p"},{"type":"text","content":"The new agreement will last for three years and include minimum annual purchasing quantities and standard termination clauses based on change of control and non-performance.","length":173,"tagName":"p"},{"type":"text","content":"Dipal Patel, Chief Commercial Officer at Valneva, commented, “We are excited to join forces with CSL Seqirus to continue developing our commercial sales in Germany. CSL’s strong commercial presence in Germany will ensure seamless distribution of our vaccines in Europe’s largest travel vaccine market, which nicely complements our in-house commercial infrastructure focused on other key markets in Europe.”","length":406,"tagName":"p"},{"type":"text","content":"Valneva’s product sales reached €48.6 million in the first quarter of 2025, including €42.8 million from its proprietary vaccines. The Company expects product sales to grow to €170-180 million in 2025, driving positive cash flows for its overall commercial business3.","length":267,"tagName":"p"},{"type":"text","content":"Abo...